Ocugen Shares Phase II OCU410 Data Showing 31% Slower GA Lesion Growth at 12 Months

Ocugen (NASDAQ:OCGN) presented top-line 12-month results from its Phase II ArMaDa clinical trial evaluating OCU410, a ...
Ophthalmology Times

Phase 2 topline data: Ocugen OCU410 reduces geographic atrophy lesion growth by 31% at 12 months

Medium-dose OCU410 met the 12-month primary endpoint, reducing GA lesion growth by 31% versus control (P < .05), with ...

Ocugen, Inc. (OCGN) Discusses Top Line Results From Phase II ArMaDa Trial of OCU410 in Geographic Atrophy Transcript

Good morning, and welcome to Ocugen's Webcast to discuss the Top Line 12-month Results from Phase II ArMaDa Clinical Trial Evaluating OCU410 for Geographic Atrophy or GA Secondary to Dry Age-related ...
The American Journal of Managed Care

Gene Therapy Well Tolerated in Wet AMD, Shows Promise in Visual Acuity

A single injection of a gene therapy was well tolerated and showed the potential to control exudation in patients with neovascular age-related macular degeneration (wet AMD). A single subretinal dose ...
Nasdaq

Lineage Announces Launch of Phase 2a Study by Genentech of RG6501 (OpRegen®) in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration

CARLSBAD, Calif.--(BUSINESS WIRE)-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, ...
Seeking Alpha

Ocugen: Two Gene Therapy Data Readouts In 2024 To Drive Value

Ocugen, Inc. (OCGN) has two upcoming data readouts expected in 2024, both of which could drive shareholder value higher. This would be regarding the use of OCU-410 and OCU-410ST, which are being ...